The Impact of COVID-19 Disease on Platelets and Coagulation
- PMID: 33049751
- PMCID: PMC7649697
- DOI: 10.1159/000512007
The Impact of COVID-19 Disease on Platelets and Coagulation
Abstract
Coronavirus disease 2019 (COVID-19) causes a spectrum of disease; some patients develop a severe proinflammatory state which can be associated with a unique coagulopathy and procoagulant endothelial phenotype. Initially, COVID-19 infection produces a prominent elevation of fibrinogen and D-dimer/fibrin(ogen) degradation products. This is associated with systemic hypercoagulability and frequent venous thromboembolic events. The degree of D-dimer elevation positively correlates with mortality in COVID-19 patients. COVID-19 also leads to arterial thrombotic events (including strokes and ischemic limbs) as well as microvascular thrombotic disorders (as frequently documented at autopsy in the pulmonary vascular beds). COVID-19 patients often have mild thrombocytopenia and appear to have increased platelet consumption, together with a corresponding increase in platelet production. Disseminated intravascular coagulopathy (DIC) and severe bleeding events are uncommon in COVID-19 patients. Here, we review the current state of knowledge of COVID-19 and hemostasis.
Keywords: COVID-19; Coagulopathy; D-dimer; Thrombocytopenia; Thrombosis.
© 2020 S. Karger AG, Basel.
Conflict of interest statement
G.D.W. is on an advisory committee at Diagnostica Stago and receives honoraria. J.L.M. declares no conflicts of interest.
Figures
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
